Page 20 - Sera News Today

Sera Prognostics (NASDAQ:SERA – Get Rating) is one of 45 publicly-traded companies in the “Medical laboratories” industry, but how does it contrast to its rivals? We will compare Sera Prognostics to similar companies based on the strength of its analyst recommendations, valuation, profitability, risk, earnings, dividends and institutional ownership. Analyst Ratings This is a breakdown […]

On composer Rajesh Roshan’s birthday, balladeer Lucky Ali recalls his days with his ‘buddy’.

Sera Prognostics (NASDAQ:SERA – Get Rating) is one of 45 publicly-traded companies in the “Medical laboratories” industry, but how does it contrast to its peers? We will compare Sera Prognostics to related companies based on the strength of its valuation, dividends, analyst recommendations, risk, earnings, institutional ownership and profitability. Profitability This table compares Sera Prognostics […]

Sera Prognostics (NASDAQ:SERA – Get Rating) is one of 45 public companies in the “Medical laboratories” industry, but how does it compare to its competitors? We will compare Sera Prognostics to related businesses based on the strength of its earnings, institutional ownership, profitability, dividends, valuation, analyst recommendations and risk. Profitability This table compares Sera Prognostics […]

Sera Prognostics (NASDAQ:SERA – Get Rating) is one of 45 publicly-traded companies in the “Medical laboratories” industry, but how does it weigh in compared to its peers? We will compare Sera Prognostics to related businesses based on the strength of its earnings, risk, profitability, institutional ownership, dividends, analyst recommendations and valuation. Insider and Institutional Ownership […]

Sera Prognostics (NASDAQ:SERA – Get Rating) is one of 45 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its peers? We will compare Sera Prognostics to related companies based on the strength of its dividends, institutional ownership, analyst recommendations, earnings, profitability, valuation and risk. Analyst Ratings This is a summary […]

Sera Prognostics (NASDAQ:SERA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Sera Prognostics Inc. is a women’s health diagnostics company. It focused on improving maternal and neonatal health by providing […]

Voices Festival Productions with the Arts Club of Washington joins a worldwide project to bear witness through theater to the horrors of Putin’s war.

Sera Prognostics (NASDAQ:SERA – Get Rating) and Viridian Therapeutics (NASDAQ:VRDN – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations. Earnings & Valuation This table compares Sera Prognostics and […]

Sera Prognostics, Inc. (NASDAQ:SERA – Get Rating) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 179,000 shares, an increase of 62.7% from the March 15th total of 110,000 shares. Based on an average daily trading volume, of 55,000 shares, the days-to-cover ratio […]